Evaluating cardiovascular risk factors in breast cancer survivors: The role of echocardiography and cardiopulmonary exercise testing in the Munich Cardio-Oncology-Exercise retrospective Registry
The most common CVDRF among BCS is hypertension, underscoring the importance of monitoring this outcome irrespective of breast cancer treatment regimens. The H<sub>2</sub>FPEF score, CPET and echocardiography may help identify BCS at risk of developing hypertension. Strain and biomarkers were not available, impeding detection of cardiotoxicity.
Authors
- Stephen Foulkes (ORCID: https://orcid.org/0000-0001-7651-3740)
- Stephan Mueller (ORCID: https://orcid.org/0000-0003-4890-3981)
- Veronika Schmid
- Martin Halle (ORCID: https://orcid.org/0000-0003-3065-530X)
- Mark J. Haykowsky (ORCID: https://orcid.org/0000-0002-7217-2747)
- Simon Wernhart (ORCID: https://orcid.org/0000-0001-6732-0939)
- Sabine Grill (ORCID: https://orcid.org/0000-0001-6735-969X)
- Marion B. Kiechle (ORCID: https://orcid.org/0000-0003-4237-2657)
- Caterina Fiorentini (ORCID: https://orcid.org/0000-0002-9346-1409)
- Simon Glowka
- Bernadine Madl
Institutions
- University of Alberta (CA)
- TUM Klinikum (DE)
- Technical University of Munich (DE)
Publication Details
- Journal
- International Journal of Cardiology
- Published
- 2025-05-25
- DOI
- https://doi.org/10.1016/j.ijcard.2025.133421
- Citations
- 2
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- University of Alberta
- Daiichi-Sankyo
- Daiichi Sankyo Europe